• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014

    Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014

  2. NYSE to expand number of companies on biotech index

    NYSE to expand number of companies on biotech index

  3. Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy

    Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy

  4. Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

    Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

  5. Research and Markets: Global Biological Drugs Market Outlook 2020

    Research and Markets: Global Biological Drugs Market Outlook 2020

  6. Research and Markets: Global Cancer Monoclonal Antibodies Market & Pipeline Insight 2014

    Research and Markets: Global Cancer Monoclonal Antibodies Market & Pipeline Insight 2014

  7. Biotech Boom, or Bubble?

    All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. The information provided in this posting is not a complete analysis of every material fact regarding any country, region, ...

  8. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.